PLGLB1: A Potential Drug Target and Biomarker (G5343)
PLGLB1: A Potential Drug Target and Biomarker
Platelet-derived growth factor (PDGF) signaling pathway has been identified as a promising target for the development of therapeutic interventions for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. PDGF signaling is a critical pathway involved in the regulation of cell proliferation, differentiation, and survival, and is implicated in many diseases, including cancer, where it has been shown to contribute to tumorigenesis and metastasis.
PLGLB1, a protein that is expressed in various tissues and cells, including platelets, neurons, and cancer cells, is a key player in the PDGF signaling pathway. It is a 21-kDa transmembrane protein that plays a critical role in the regulation of cell proliferation and survival. PLGLB1 has been shown to be involved in the regulation of cell proliferation, differentiation, and survival, and is a potential drug target in various diseases.
The PLGLB1 signaling pathway is involved in the regulation of cell proliferation and has been implicated in the development and progression of many diseases, including cancer. For example, PLGLB1 has been shown to be involved in the regulation of cell proliferation in various tissues, including the brain, where it has been shown to contribute to the development of neurodegenerative disorders.
PLGLB1 has also been shown to be involved in the regulation of cell survival and has been implicated in the development of many diseases, including cancer. For example, PLGLB1 has been shown to be involved in the regulation of cell survival in cancer cells, where it has been shown to contribute to tumorigenesis and metastasis.
PLGLB1 is also involved in the regulation of cell adhesion and has been shown to play a critical role in the development of various diseases, including cancer. For example, PLGLB1 has been shown to be involved in the regulation of cell adhesion in cancer cells, where it has been shown to contribute to tumor cell migration and the development of invasive tumors.
In conclusion, PLGLB1 is a protein that is involved in the regulation of many cellular processes and has been implicated in the development and progression of many diseases. As a potential drug target, PLGLB1 may be a useful target for the development of therapeutic interventions for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Further research is needed to fully understand the role of PLGLB1 in the regulation of cellular processes and to develop effective therapeutic interventions based on this protein.
Protein Name: Plasminogen Like B1
Functions: May bind noncovalently to lysine binding sites present in the kringle structures of plasminogen. This may interfere with the binding of fibrin or alpha-2-antiplasmin to plasminogen and may result in the localization of activity at sites necessary for extracellular matrix destruction
More Common Targets
PLGLB2 | PLGRKT | PLIN1 | PLIN2 | PLIN3 | PLIN4 | PLIN5 | PLK1 | PLK2 | PLK3 | PLK4 | PLK5 | PLLP | PLN | PLOD1 | PLOD2 | PLOD3 | PLP1 | PLP2 | PLPBP | PLPP1 | PLPP2 | PLPP3 | PLPP4 | PLPP5 | PLPP6 | PLPP7 | PLPPR1 | PLPPR2 | PLPPR3 | PLPPR4 | PLPPR5 | PLPPR5-AS1 | PLRG1 | PLS1 | PLS3 | PLSCR1 | PLSCR2 | PLSCR3 | PLSCR4 | PLSCR5 | PLTP | PLUT | PLVAP | PLXDC1 | PLXDC2 | PLXNA1 | PLXNA2 | PLXNA3 | PLXNA4 | PLXNB1 | PLXNB2 | PLXNB3 | PLXNC1 | PLXND1 | PM20D1 | PM20D2 | PMAIP1 | PMCH | PMCHL1 | PMCHL2 | PMEL | PMEPA1 | PMF1 | PMF1-BGLAP | PMFBP1 | PML | PMM1 | PMM2 | PMP2 | PMP22 | PMPCA | PMPCB | PMS1 | PMS2 | PMS2P1 | PMS2P12 | PMS2P13 | PMS2P2 | PMS2P3 | PMS2P4 | PMS2P5 | PMS2P9 | PMVK | PNCK | PNISR | PNISR-AS1 | PNKD | PNKP | PNKY | PNLDC1 | PNLIP | PNLIPRP1 | PNLIPRP2 | PNLIPRP3 | PNMA1 | PNMA2 | PNMA3 | PNMA5 | PNMA6A